Status:

TERMINATED

GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Lead Sponsor:

jianming xu

Conditions:

Advanced Hepatocellular Carcinoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Detailed Description

This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of CART cell in patients ≥ 18 years of age with relapsed or refractory advanced hepatocellular c...

Eligibility Criteria

Inclusion

  • Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent;
  • Age 18-75 years;
  • Patients diagnosed as advanced hepatocellular carcinoma (HCC) histopathologically or cytologically; Progression or intolerance after previous standard systemic therapy;
  • GPC3 is detected positive by immunohistochemistry (IHC);
  • Child-Pugh score ≤ 7;
  • At least one assessable tumor lesion;
  • ECOG score: 0-1;
  • Expected survival ≥ 3 months;
  • Clinical laboratory values meet screening visit criteria

Exclusion

  • Previous CAR-T cell, TCR-T cell or other cell therapies or therapeutic tumor vaccination directed at any target;
  • Any previous GPC3 targeted therapy;
  • Prior antitumor therapy with insufficient washout period;
  • Brain metastases with central nervous system symptoms;
  • Pregnant or lactating women
  • HCV-Ab or/and HIV-Ab positive; active syphilis;
  • Severe underlying diseases
  • Any condition that, in the opinion of the investigator, will make the subject unsuitable for participation in this study.

Key Trial Info

Start Date :

May 19 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 31 2024

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT05352542

Start Date

May 19 2022

End Date

July 31 2024

Last Update

August 9 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Beijing Gobroad Boren Hospital

Beijing, Beijing Municipality, China

2

Chinese PLA General Hospital

Beijing, Beijing Municipality, China